The authors review a House Oversight Committee investigation report on AbbVie’s practices pertaining to adalimumab (Humira) to shed light on broader pharmaceutical market dynamics hindering a competitive market.
Micaela Laber, MPH, MBA
Advertisement
Articles by Micaela Laber, MPH, MBA
Advertisement
Latest Updated Articles
- Humira: The First $20 Billion Drug
Published: February 8th 2023 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 Vaccination Linked to Lower Risk of Long COVID in Adolescents
2
Medicaid Work Requirements Set to Leave Millions Without Insurance
3
Adherence Support May Improve Viral Suppression in Incarcerated Patients With HIV
4
Changing Tumor Classifications May Explain Rise in Early-Onset CRC
5
